ESPR
NASDAQEsperion Therapeutics Inc.
Price$1.92+0.05 (+2.68%)
01:30 PM07:45 PM
News · 26 weeks55-40%
2025-10-262026-04-19
Mix2890d
- Other12(43%)
- SEC Filings6(21%)
- Insider6(21%)
- Earnings4(14%)
Latest news
25 items- PREsperion to Report First Quarter 2026 Financial Results on May 7ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical c
- SECSEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.SCHEDULE 13G - Esperion Therapeutics, Inc. (0001434868) (Subject)
- SECSEC Form DEFA14A filed by Esperion Therapeutics Inc.DEFA14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form DEF 14A filed by Esperion Therapeutics Inc.DEF 14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECEsperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- PRAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka's bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 millionAthyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to EsperionFinancing supports Esperion's acquisition of Corstasis Therapeutics Inc., which developed and is commercializing Enbumyst™, the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular and hepatic and renal disease NEW YORK a
- PREsperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. "The closing of this acquisition marks an important milestone in advancing our Vision 2040 and strengthens our commitm
- PREsperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therap
- PREsperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026– Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID – ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of two post-hoc analyses from CLEAR Outcomes focused on risk of ischemic stroke and risk of major adverse cardiovascular events (MACE) in patients with autoimmune or inflammatory diseases. These data were presented as moderated poster presentations at the American College of Cardiology's Annual Scie
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Esperion Therapeutics Inc.SCHEDULE 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
- INSIDERSEC Form 4 filed by Koenig Sheldon L.4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERSEC Form 4 filed by Looker Benjamin4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERSEC Form 4 filed by Halladay Benjamin4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- PREsperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific SessionReviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology's 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA. "ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world's leading cardiologists," said Sheldon Koenig, Chief Executive Officer of Esperion. "These analyses deepen our u
- INSIDERChief Legal Officer Looker Benjamin was granted 300,840 shares, increasing direct ownership by 78% to 685,056 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERPresident and CEO Koenig Sheldon L. was granted 723,760 shares, increasing direct ownership by 49% to 2,198,277 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERChief Financial Officer Halladay Benjamin was granted 247,430 shares, increasing direct ownership by 52% to 720,026 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- PREsperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Longer is Better' Approach to Cardiovascular Risk Reduction – ANN ARBOR, Mich., March 16, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering
- SECSEC Form 10-K filed by Esperion Therapeutics Inc.10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECEsperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- PREsperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co
- PRHLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular DiseaseFirst-in-class, once-daily oral non-statin therapy now available by prescription across CanadaAddresses a significant unmet need for over half a million Canadians who can not get to their LDL-C goal on statin-based therapy or who are statin intolerantSupported by the landmark CLEAR Outcomes trial demonstrating reduction in major adverse cardiovascular events in nearly 14,000 patientsTORONTO, March 5, 2026 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now ava
- SECEsperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- PREsperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p
- PREsperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmac